Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 10, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Prognostic markers in peripheral T-cell lymphoma.

Pier Paolo Piccaluga1, Claudio Agostinelli, Anna Gazzola

  • 1Department of Hematology and Oncological Sciences "L. and A. Seràgnoli", S. Orsola-Malpighi Hospital, University of Bologna, Italy. pierpaolo.piccaluga@unibo.it

Current Hematologic Malignancy Reports
|August 7, 2010
PubMed
Summary

The International Prognostic Index (IPI) offers some prognostic value for peripheral T-cell lymphomas (PTCLs), but new, disease-specific scores are needed. Research is exploring clinical and molecular factors for better PTCL prognostication.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-step next-generation sequencing of immunoglobulin heavy chain genes to detect clonality in classical Hodgkin lymphoma.

Polish journal of pathology : official journal of the Polish Society of Pathologists·2026
Same author

The different face of skin-rash induced by brentuximab vedotin.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026
Same author

Sponge-like sonographic pattern of the spleen in immune dysregulation disorders.

Frontiers in immunology·2026
Same author

Lymphoproliferation in inborn errors of immunity: From challenging diagnosis to histologic revision.

Journal of human immunity·2026
Same author

B-cell and plasma cell proliferations associated with T follicular helper cell lymphomas: clinical-pathological and genetic features.

Virchows Archiv : an international journal of pathology·2026
Same author

Modern and multidisciplinary care in polycythemia vera.

Annals of hematology·2026

Area of Science:

  • Hematology
  • Oncology
  • Pathobiology

Background:

  • Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of aggressive non-Hodgkin lymphomas.
  • Accurate prognostication is crucial for guiding treatment decisions in PTCL patients.
  • Existing prognostic models, like the International Prognostic Index (IPI), have limitations in predicting outcomes for specific PTCL subtypes.

Purpose of the Study:

  • To review the pathobiological characteristics of PTCLs and evaluate available prognostic indicators.
  • To discuss the efficacy and limitations of current prognostic scores for PTCLs.
  • To highlight emerging prognostic factors and the need for novel, disease-specific models.

Main Methods:

  • Literature review and synthesis of existing data on PTCL pathobiology and prognostication.

More Related Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Related Experiment Videos

Last Updated: Jun 10, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

  • Analysis of the performance of the International Prognostic Index (IPI) and its modifications (e.g., PIT, Bologna score).
  • Exploration of novel prognostic factors identified through gene expression profiling and molecular studies.

    • Main Results:

    • The IPI shows partial efficiency for PTCLs but is less satisfactory for PTCL not otherwise specified (PTCL/NOS) and angioimmunoblastic T-cell lymphoma (AITL).
    • Revised scores like the Prognostic Index for PTCL-U (PIT) and the Bologna score have been proposed, integrating clinical and biological features, but require further validation.
    • Molecular factors such as NFκB pathway inactivation, high proliferation gene expression, and cytotoxic phenotype are associated with poorer outcomes but lack independent validation.

    Conclusions:

    • While the IPI is a useful tool, its limitations necessitate the development of more refined and disease-specific prognostic scores for PTCLs.
    • Integrating clinical, pathological, and molecular data holds promise for improving PTCL prognostication.
    • Ongoing validation of novel models is essential for clinical application in PTCL management.